|
[缺乏进行试验的行业激励措施]
HAIC研究潜在障碍：缺乏行业激励
日期：2021-12-28 21:43:21
点击：99
Lack of Industry Incentive for Conducting Trials 开展试验缺乏行业激励 The patents for the main chemotherapeutic agents used in HAIC, including cisplatin, oxaliplatin, 5-FU, and epirubicin, have expired, thus weakening the motivation for th...
[缺乏技术标准]
HAIC研究潜在障碍：技术标准化不足
日期：2021-12-28 13:45:34
点击：99
Insufficient Technical Standardization Techniques and protocols for HAIC have yet to be standardized. HAIC的技术和方案尚未标准化。 The efficacy and safety of HAIC depend substantially on the quality of vascular redistribution. HAIC的有效性...
[重复导管 vs 动脉港]
HAIC研究潜在障碍：重复导管术 vs 药盒置入
日期：2021-12-28 13:34:36
点击：99
Two different percutaneous arterial access approaches have been used for HAIC: the first approach entails the use of implantable port-catheter systems, and the second approach involves repeated hepatic artery catheterization. 两种不同的经...
[多种化疗方案]
HAIC研究的潜在障碍：多种化疗方案
日期：2021-12-28 11:54:22
点击：99
A standard chemotherapy regimen for HAIC has yet to be established, increasing the challenge of interpreting trial results. HAIC的标准化疗方案尚未建立，这增加了解释试验结果的挑战。 Cisplatin and 5-FU were the most commonly used chemotherap...
[异质性患者数据]
HAIC研究潜在障碍：数据的异质性
日期：2021-12-27 15:27:25
点击：99
Studies on HAIC have included populations with various degrees of intrahepatic tumor burden, including the possible presence of PVT/EHS. 对HAIC的研究包括了不同程度肝内肿瘤负荷的人群，包括可能存在PVT/EHS。 Studies on patients with PVT who r...
[+ 免疫治疗]
HAIC 联合免疫治疗
日期：2021-12-27 08:50:24
点击：99
Immune checkpoint inhibitorbased combinations have changed the treatment paradigm for advanced HCC [59,60] and are likely to remain the cornerstone of systemic treatment in the next few years. 基于免疫检查点抑制剂的联合治疗已经改变了晚期HC...
[+ 放疗]
HAIC 联合放疗
日期：2021-12-25 11:25:23
点击：99
HAIC combined with radiation therapy (RT) has also been extensively investigated, particularly in subgroups of patients with PVT. HAIC联合放疗(RT)也已被广泛研究，特别是在PVT患者的亚组中。 Han et al. [ 51 ] conducted a small-scale single-ar...
[+ 多激酶抑制剂]
HAIC联合多激酶抑制剂
日期：2021-12-25 07:06:16
点击：99
HAIC has been combined with sorafenib to leverage the synergistic effects of the combination. HAIC已与索拉非尼联合使用，以利用该联合使用的协同效应。 A randomized Phase 2 trial was conducted to compare HAIC plus sorafenib with sorafenib alo...
[+ 干扰素α]
HAIC联合皮下干扰素α
日期：2021-12-24 23:56:05
点击：99
Subcutaneous or intramuscular interferon-alpha (IFN-) has been used in combination with intravenous chemotherapy for advanced HCC to enhance antitumor activity [55]. 皮下或肌内干扰素(IFN-)已与静脉化疗联合用于晚期HCC，以增强抗肿瘤活性[ 55 ]...
[产后出血的病因]
产后出血的病因
日期：2021-12-20 23:54:01
点击：474
子宫松弛 子宫弛缓发生率大约为1/20，是由于胎盘排出后子宫肌层不能收缩以控制失血造成的。危险因子包括导致子宫过度扩张（多胎妊娠和羊水过多）、子宫脆弱（过期妊娠或者绒毛膜羊膜炎）的情况和子宫由于外因而收缩受限（使用子宫松弛药物或者全身麻醉）。子...
在COVID大流行期间，全球因COVID肺炎导致的急性呼吸窘迫综合征(ARDS)导致的死亡人数大...
endograft exclusion 腔内移植物隔绝术治疗内脏动脉瘤（VAA），毋庸赘言是应为内脏动...
门静脉系统因狭窄(24%)或闭塞(12%)导致减压丧失 复发性门静脉高压症; 静脉曲张的出血;...
Mara Reig 医生是一位兼具临床与科研能力的医师科学家，目前任职包括巴塞罗那 Hospita...
胫动脉PTA的技术难点包括需要用小轴径球囊导管，细导丝，操作时大量的使用肝素、血管...
单纯使用球囊扩张血管（POBA）有一个无法避免的致命缺陷，那就是治疗后血管很容易再次...
